Appendicitis caused by the metastasis of HER2-positive breast cancer

被引:1
|
作者
Mori, Ryutaro [1 ]
Futamura, Manabu [1 ]
Morimitsu, Kasumi [1 ]
Yoshida, Kazuhiro [1 ]
机构
[1] Gifu Univ, Grad Sch Med, Dept Surg Oncol, 1-1 Yanagido, Gifu 5011194, Japan
来源
SURGICAL CASE REPORTS | 2016年 / 2卷
关键词
Secondary appendiceal neoplasm; Appendicitis; Lobular carcinoma;
D O I
10.1186/s40792-016-0235-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
The appropriate therapy for metastatic breast cancer must be selected based on the immunohistochemical phenotype of the cancer. However, biopsy for metastatic lesions is difficult. We herein report a patient with incidental appendicitis caused by a metastatic breast cancer which was successfully treated with effective therapy chosen based on the pathological diagnosis obtained on resection. The patient was a 56-year-old female with right breast cancer and an immunohistochemical status of estrogen receptor (ER) (+), progesterone receptor (PgR) (+), human epidermal growth factor receptor 2 (HER2) (3+), and Ki67 40 %. She received epirubicin and cyclophosphamide therapy followed by docetaxel and trastuzumab, and total mastectomy with axillary dissection was performed. Thereafter, she received postmastectomy radiation, adjuvant trastuzumab, and adjuvant hormone therapy with letrozole. One year and 8 months after the operation, she developed right hydronephrosis and swollen para-aortic lymph nodes and her hormone therapy was changed to fulvestrant therapy. However, she additionally developed left hydronephrosis and multiple bone metastases, and pertuzumab, trastuzumab, and docetaxel therapy was started. After six cycles, her disease became well-controlled, and maintenance with pertuzumab and trastuzumab was introduced. However, after another 7 months, she developed new vertebral metastasis and acute appendicitis and laparoscopic appendectomy was performed. A pathological investigation of the resected appendix revealed some clusters of atypical cells in the subserosa and muscle layer, which showed an immunohistochemical status of ER (+), PgR (-), HER2 (3+), and E-cadherin (-). These findings led to the diagnosis as appendiceal metastasis of invasive lobular carcinoma (ILC) from the breast. Thereafter, she received trastuzumab-DM1 and her disease was well-controlled again. Appendicitis caused by breast cancer is very rare. However, ILC sometimes develops metastases in the abdominal cavity; an appendiceal tumor should therefore be included in the differential diagnosis. A pathological diagnosis of metastatic tumor could be very useful for selecting the effective therapy.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Adjuvant treatment for HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (02): : E59 - E59
  • [32] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [33] Treatment Combinations for HER2-Positive Breast Cancer
    Pegram, Mark
    ONCOLOGY-NEW YORK, 2013, 27 (04): : 258 - +
  • [34] Management of HER2-Positive Early Breast Cancer
    Steger, Guenther
    Lueftner, Diana
    Stoeger, Herbert
    Thurlimann, Beat
    Untch, Michael
    BREAST CARE, 2018, 13 (06) : 453 - 455
  • [35] Is there a role for immunotherapy in HER2-positive breast cancer?
    Esther Holgado
    Jose Perez-Garcia
    Maria Gion
    Javier Cortes
    npj Breast Cancer, 4
  • [36] Treatment strategy for HER2-positive breast cancer
    Mukai, Hirofumi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) : 335 - 340
  • [37] Expert Discussion: HER2-Positive Breast Cancer
    Foukakis, Theodoros
    Matikas, Alexios
    Oikonomidou, Olga
    Andreopoulou, Eleni
    Mavroudis, Dimitris
    BREAST CARE, 2021, 16 (04) : 422 - 428
  • [38] Updates in HER2-Positive Metastatic Breast Cancer
    Gadi, V. K.
    Iyengar, Neil
    Isaacs, Claudine
    Kaklamani, Virginia
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 588 - 591
  • [39] Neratinib in HER2-Positive Breast Cancer Patients
    Paranjpe, Rutugandha
    Basatneh, Dima
    Tao, Gabriel
    De Angelis, Carmine
    Noormohammed, Sobia
    Ekinci, Ekim
    Abughosh, Susan
    Ghose, Romi
    Trivedi, Meghana V.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 612 - 620
  • [40] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415